Clinical Trial Update: The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for Toca 511 & Toca FC in recurrent high-grade glioma (Phase 2/3) has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Glioblastoma

Drugs mentioned

• Toca 511 (retroviral replicating vector expressing cytosine deaminase)
• Toca FC (5-fluorocytosine)

Snippet

Sponsor: Tocagen Inc. | Conditions: Glioblastoma Multiforme, Anaplastic Astrocytoma | Phase 2, Phase 3 | Status: TERMINATED